Deck Bio
Multi-target T cell engagers redirecting immunity against intracellular cancer antigens in solid tumors.
Category Biotech Company
Ternary Therapeutics
AI-driven platform designing molecular glue therapeutics for undruggable targets in immunology and neuroinflammation.
Stipple Bio
Epitope-resolution platform discovering tumor-specific cell surface targets for precision ADCs and next-generation oncology therapeutics.
TRIANA Biomedicines
Rational molecular glue degrader platform targeting undruggable oncology targets, with lead ALK fusion degrader in Phase 1/2 for NSCLC.
Commit Biologics
Bispecific complement engagers recruiting the innate immune system for B-cell depletion in autoimmune disease and cancer.
Neutrolis
Neutrolis is developing the first therapy designed to degrade neutrophil extracellular traps — attacking one of the root causes of autoimmunity without immunosuppression.
AvenCell Therapeutics
AvenCell just dosed the first patient with a CRISPR-engineered allogeneic CAR-T that simultaneously targets CD19 and CD20 — with a built-in switchable receptor that lets you retarget the same cells post-infusion.
Alltrna
Alltrna just put the first engineered tRNA therapeutic into a human trial, creating an entirely new drug class to address them.
Antiverse
Antiverse is using generative AI to crack the 220 undrugged GPCRs that conventional discovery can't touch.
NEOK Bio
NEOK is building on of the most ambitious bispecific ADC pipeline to hit the U.S. clinic.